Lipids in chronic kidney disease.

Area of Science:

• Nephrology
• Cardiology
• Lipidology

Background:

• Patients with chronic kidney disease (CKD) experience premature cardiovascular disease (CVD).
• Lipid metabolism is significantly disturbed in CKD patients, with elevated triglycerides, reduced HDL, and increased small, dense LDL particles.
• The relationship between lipids and vascular disease in CKD is complex and differs from the general population.

Purpose of the Study:

• To investigate the role of blood lipids in the development of vascular disease in CKD patients.
• To explore the potential of lipid modification to delay the progression of CKD.
• To evaluate the effectiveness of statins in reducing vascular and renal risk in CKD.

Main Methods:

• Review of existing randomized trials on lipid-lowering therapies in CKD.
• Analysis of data on the association between lipid fractions and vascular disease in CKD.
• Anticipation of results from the ongoing Study of Heart and Renal Protection (SHARP) trial.

Main Results:

• Randomized trials in the general population show statins reduce vascular events.
• Current evidence on lipid modification's impact on vascular disease in CKD is inconclusive.
• Data on lipid modification's effect on CKD progression is limited, primarily based on surrogate markers like proteinuria.

Conclusions:

• The relevance of blood lipids to vascular disease in CKD requires further investigation through randomized trials.
• Lipid modification may potentially slow CKD progression, but more definitive data is needed.
• The SHARP trial is expected to provide crucial insights into the benefits of statins for both cardiovascular and renal outcomes in CKD.